Trial Profile
A Multicenter Phase 3 Study Comparing the Diagnostic Accuracy of 99mTc EC DG SPECT/CT Versus 18F FDG PET/CT for Diagnosing and Staging Patients Who Have Clinical and Radiological (CT) Evidence Consistent With a Diagnosis of Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Tc 99m ethylenedicysteine deoxyglucose (Primary) ; Fludeoxyglucose F-18
- Indications Lung cancer
- Focus Diagnostic use
- Sponsors CellPoint
- 28 Jan 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2023.
- 28 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.
- 28 Jan 2021 Status changed from recruiting to active, no longer recruiting.